Skip to main content
. 2021 Dec 15;131(24):e145501. doi: 10.1172/JCI145501

Figure 6. Orally formulated ruxolitinib plus CD45-SAP or cKit-SAP promotes robust, stable engraftment in miHA- and fully MHC-mismatched allo-HSCT.

Figure 6

(A and B) Schematic for miHA- (A) and fully MHC-mismatched (B) HSCT with ADC conditioning plus ruxolitinib chow. (C and D) Donor chimerism in individual miHA-mismatched (C) and fully mismatched (D) HSCT recipients conditioned with CD45-SAP plus ruxolitinib chow, pooled from 3 experiments. (E and F) Donor chimerism in individual miHA-mismatched (E) and fully mismatched (F) HSCT recipients conditioned with cKit-SAP plus ruxolitinib chow, pooled from 3 experiments. X indicates mouse death or euthanasia. Repeated measures ANOVA (C, D, F) and a mixed effects model (E) were used for statistical comparisons of overall donor chimerism. ***P < 0.001; ****P < 0.0001.